Avicanna Q2 Revenue Improves 85% YoY, Cannabis Company Touts Two Successful Trials On Drug Candidates
Portfolio Pulse from Nina Zdinjak
Avicanna Inc. reported an 85% YoY increase in Q2 revenue to CA$6.1 million. The company also completed two successful trials on drug candidates, showing significant improvements in patient conditions. Despite a net loss of CA$1.95 million, the adjusted EBITDA loss narrowed by 65%.
August 15, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avicanna Inc. reported an 85% YoY increase in Q2 revenue to CA$6.1 million and completed two successful trials on drug candidates. Despite a net loss of CA$1.95 million, the adjusted EBITDA loss narrowed by 65%.
The significant YoY revenue growth and successful drug trials are positive indicators for Avicanna's future performance. The narrowing of the adjusted EBITDA loss further strengthens the company's financial position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100